An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti‐Angiogenic Agents for Therapy: A Case Report

ABSTRACT Background Although the presence of Kirsten murine sarcoma virus (KRAS) mutations predicts a failure of non‐small cell carcinoma (NSCLC) patients to benefit from epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitor (TKI) therapy it may be more sensitive to programmed combinatio...

Full description

Bibliographic Details

Published in:	Cancer Reports
Main Authors:	Li Wang, Jiaqi Wu, Ping Shao, Wuping Bao, Lin Mao, Zhendong Pan, Aihua Bao, Min Zhang, Zhenghua Wu, Guorong Fan
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Subjects:	anti‐angiogenic agents camrelizumab case report KRAS mutations lung adenocarcinoma
Online Access:	https://doi.org/10.1002/cnr2.70186